HR+HER2- Breast Cancer

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

Phase Ib Study of Neoadjuvant DPX-Survivac, Aromatase Inhibition, and with/without Radiotherapy or Cyclophosphamide in HR+HER2- Breast CancerThe study seeks to establish the safety of neoadjuvant aromatase inhibitor with: DPX-Survivac, DPX-Survivac plus radiation, or DPX-Survivac with cyclophosphamide in stage I to III HR+HER2- breast cancer. There will be sequential enrollment into 3 arms with an anticipated N=6 participants per arm for N=18 participants in total. All participants will receive letrozole 2.5 mg daily during the 6 weeks of neoadjuvant therapy. Neoadjuvant therapy occurs weeks 1-6, with standard of care surgery taking place week 7 to 9.

Inclusions/Exclusions: ECOG 0-1. No HIV or HEP. No prior BC or AI, tamoxifen use.

Learn More.